The SURVIVE trial of the targeted vaccine SurVaxM did not meet its primary OS end point due to longer-than-expected survival with standard of care in glioblastoma but showed benefit in patients aged 65 and below.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
AI in Precision Oncology: A Paradigm Shift
2
Prostate and Rare Cancer Agents Nab FDA Fast Track Status
3
Dr Bazhenova on Taletrectinib Label Update and Subgroup Data in ROS1+ NSCLC
4
FDA Approves Adjuvant Atezolizumab Plus Chemo for dMMR Colon Cancer
5